By KYIV. Jan 16 (Interfax-Ukraine) – Pharmaceutical company Darnitsa (Kyiv) in 2022 slightly reduced the production of medicines in kind – from 181 million packages in 2021 to 173 million packages in 2022, the company has told Interfax-Ukraine.
At the same time, according to its press release, Darnitsa occupies 15.7% of the Ukrainian pharmaceutical market, which is twice as much as the nearest competitor.
"If in 2021 every seventh package of medicines sold in pharmacies was produced by Darnitsa, then in 2022 it is already every sixth package," the company said in the press release.
In total, in 2022, the company produced about 19 million vials, 9 million infusion solutions and 130 million tablets and capsules.
At the same time, Darnitsa did not stop working from the first days of the full-scale war. In March, it produced 60% of the pre-war volume of medicines, since April it returned to pre-war production volumes in full.
PrJSC Pharmaceutical company Darnitsa is the leader of the Ukrainian pharmaceutical market in kind. The company has been on the market for over 90 years and produces 180 drug brands in 15 different forms. The strategic areas of portfolio development are cardiology, neurology, pain management.
The company was founded in 1930. According to the unified public register of legal entities and sole proprietors, the ultimate beneficiary of the company is Hlib Zahoriy.
